Dupilumab efficacy in children with uncontrolled, moderate-to-severe asthma with and without an allergic phenotype
N. Papadopoulos (Manchester, United Kingdom), S. Szefler (Aurora, CO, United States of America), L. Bacharier (Nashville, TN, United States of America), J. Maspero (Buenos Aires, Argentina), C. Domingo (Barcelona, Spain), N. Daizadeh (Cambridge, MA, United States of America), D. Lederer (Tarrytown, NY, United States of America), M. Hardin (Cambridge, MA, United States of America), J. Jacob-Nara (Cambridge, MA, United States of America), Y. Deniz (Tarrytown, NY, United States of America), R. Gall (Tarrytown, NY, United States of America), B. Ortiz (Tarrytown, NY, United States of America), M. Djandji (Cambridge, MA, United States of America), P. Rowe (Bridgewater, NJ, United States of America)
Source: Virtual Congress 2021 – Advances in childhood asthma: biologics, biomarkers and infections
Rating:
You must login to grade this presentation.
Share or cite this content
Citations should be made in the following way:
N. Papadopoulos (Manchester, United Kingdom), S. Szefler (Aurora, CO, United States of America), L. Bacharier (Nashville, TN, United States of America), J. Maspero (Buenos Aires, Argentina), C. Domingo (Barcelona, Spain), N. Daizadeh (Cambridge, MA, United States of America), D. Lederer (Tarrytown, NY, United States of America), M. Hardin (Cambridge, MA, United States of America), J. Jacob-Nara (Cambridge, MA, United States of America), Y. Deniz (Tarrytown, NY, United States of America), R. Gall (Tarrytown, NY, United States of America), B. Ortiz (Tarrytown, NY, United States of America), M. Djandji (Cambridge, MA, United States of America), P. Rowe (Bridgewater, NJ, United States of America). Dupilumab efficacy in children with uncontrolled, moderate-to-severe asthma with and without an allergic phenotype. 2568
You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
Related content which might interest you:
Related content which might interest you: